drugset / Trial / NCT06604325
Prophylactic Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery.
RandomizedParallel-groupDouble-blindPrevention
Summary
Postpartum hemorrhage continues to be the leading cause of maternal morbidity and mortality. Globally, it is responsible for 25% of all pregnancy-related deaths. PPH is unpredictable and may occur in the absence of risk factors. Tranexamic acid is an antifibrinolytic proven to reduce blood loss and transfusion requirements for various surgeries. This study aims to explore the effectiveness of tranexamic acid as an adjunct to other uterotonics before the Caesarian Section.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2025-03-30
- Completion
- 2025-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tranexamic Acid | Small molecule | 1 g | Intravenous |
Indications
No indication recorded.